Spoken Alpha
PLX
Protalix BioTherapeutics, Inc.
Overview
Protalix BioTherapeutics develops and manufactures biopharmaceutical treatments for rare diseases using its proprietary plant cell-based protein expression platform called ProCellEx.
Protalix BioTherapeutics, Inc is a Healthcare company operating in Biotechnology with a $174.8M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 12, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-137 Q&A exchanges
- Q4 FY2025Earnings2026-03-187 Q&A exchanges
- Q3 FY2025Earnings2025-11-1316 Q&A exchanges
- Q2 FY2025Earnings2025-08-146 Q&A exchanges
- Q1 FY2025Earnings2025-05-0915 Q&A exchanges
- Q4 FY2024Earnings2025-03-1712 Q&A exchanges
- Q3 FY2024Earnings2024-11-1415 Q&A exchanges
- Q2 FY2024Earnings2024-08-1412 Q&A exchanges
- Q1 FY2024Earnings2024-05-1016 Q&A exchanges
- Q4 FY2023Earnings2024-03-148 Q&A exchanges
- Q3 FY2023Earnings2023-11-0612 Q&A exchanges
- Q2 FY2023Earnings2023-08-0714 Q&A exchanges
- Q1 FY2023Earnings2023-05-048 Q&A exchanges
- Q4 FY2022Earnings2023-02-2717 Q&A exchanges
- Q3 FY2022Earnings2022-11-1412 Q&A exchanges
- Q2 FY2022Earnings2022-08-1511 Q&A exchanges
- Q1 FY2022Earnings2022-05-166 Q&A exchanges
- Q4 FY2021Earnings2022-03-318 Q&A exchanges
- Q3 FY2021Earnings2021-11-1511 Q&A exchanges
- Q2 FY2021Earnings2021-08-1610 Q&A exchanges
- Q1 FY2021Earnings2021-05-1411 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-12EPS— vs $-0.03—Rev— vs ——EODHD
- Q1 FY20262026-05-07EPS$0.22 vs $0.06+100.0%Rev$33.8M vs ——EODHD
- Q4 FY20252026-03-11EPS$-0.07 vs $0.04-100.0%Rev$9.1M vs ——EODHD
- Q3 FY20252025-11-12EPS$0.03 vs $0.07-57.1%Rev$17.9M vs ——EODHD
- Q2 FY20252025-08-13EPS$-0.04 vs $0.11-100.0%Rev$15.7M vs ——EODHD
- Q1 FY20252025-05-07EPS$-0.05 vs $-0.02-100.0%Rev$10.1M vs ——EODHD
- Q4 FY20242025-03-11EPS$0.09 vs $0.07+28.6%Rev$18.2M vs ——EODHD
- Q3 FY20242024-11-03EPS$0.03 vs $0.06-50.0%Rev$18.0M vs ——EODHD
- Q2 FY20242024-08-13EPS$-0.03 vs $0.02-100.0%Rev$13.5M vs ——EODHD
- Q1 FY20242024-05-09EPS$-0.06 vs $-0.02-100.0%Rev$3.7M vs ——EODHD
- Q4 FY20232024-03-13EPS$-0.07 vs $-0.03-100.0%Rev$10.5M vs ——EODHD
- Q3 FY20232023-11-05EPS$-0.04 vs $-0.07+42.9%Rev$10.3M vs ——EODHD
- Q2 FY20232023-08-06EPS$0.21 vs $-0.04+100.0%Rev$35.1M vs ——EODHD
- Q1 FY20232023-05-03EPS$-0.05 vs $-0.050.0%Rev$9.6M vs ——EODHD
- Q4 FY20222023-02-26EPS$-0.07 vs $-0.15+53.3%Rev$8.6M vs ——EODHD
- Q3 FY20222022-11-13EPS$-0.07 vs $-0.15+53.3%Rev$14.2M vs ——EODHD
- Q2 FY20222022-08-14EPS$-0.11 vs $-0.18+38.9%Rev$8.8M vs ——EODHD
- Q1 FY20222022-05-15EPS$-0.05 vs $-0.04-25.0%Rev$16.1M vs ——EODHD
- Q4 FY20212022-03-30EPS$-0.15 vs $-0.11-36.4%Rev$8.5M vs ——EODHD
- Q3 FY20212021-11-14EPS$-0.09 vs $-0.12+25.0%Rev$12.1M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | — | $-0.03 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-07 | $0.22 | $0.06 | +100.0% | $33.8M | — | — | EODHD |
| Q4 FY2025 | 2026-03-11 | $-0.07 | $0.04 | -100.0% | $9.1M | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $0.03 | $0.07 | -57.1% | $17.9M | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-0.04 | $0.11 | -100.0% | $15.7M | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $-0.05 | $-0.02 | -100.0% | $10.1M | — | — | EODHD |
| Q4 FY2024 | 2025-03-11 | $0.09 | $0.07 | +28.6% | $18.2M | — | — | EODHD |
| Q3 FY2024 | 2024-11-03 | $0.03 | $0.06 | -50.0% | $18.0M | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-0.03 | $0.02 | -100.0% | $13.5M | — | — | EODHD |
| Q1 FY2024 | 2024-05-09 | $-0.06 | $-0.02 | -100.0% | $3.7M | — | — | EODHD |
| Q4 FY2023 | 2024-03-13 | $-0.07 | $-0.03 | -100.0% | $10.5M | — | — | EODHD |
| Q3 FY2023 | 2023-11-05 | $-0.04 | $-0.07 | +42.9% | $10.3M | — | — | EODHD |
| Q2 FY2023 | 2023-08-06 | $0.21 | $-0.04 | +100.0% | $35.1M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-0.05 | $-0.05 | 0.0% | $9.6M | — | — | EODHD |
| Q4 FY2022 | 2023-02-26 | $-0.07 | $-0.15 | +53.3% | $8.6M | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.07 | $-0.15 | +53.3% | $14.2M | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-0.11 | $-0.18 | +38.9% | $8.8M | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.05 | $-0.04 | -25.0% | $16.1M | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $-0.15 | $-0.11 | -36.4% | $8.5M | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-0.09 | $-0.12 | +25.0% | $12.1M | — | — | EODHD |
Source: EODHD. PLX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks PLX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 60% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.25 | $2.34 | +39.0% | -0.4% | -1.2% |
| Q4 FY2026 | $2.91 | $2.16 | +34.7% | -4.0% | -5.3% |
| Q3 FY2026 | $2.80 | $2.20 | +27.4% | -0.6% | +2.0% |
| Q2 FY2026 | $2.94 | $2.31 | +27.2% | +5.0% | +5.2% |
| Q1 FY2025 | $3.17 | $2.40 | +32.1% | -1.4% | -0.5% |
| Q4 FY2025 | $3.22 | $2.31 | +39.6% | -2.4% | +0.4% |
| Q3 FY2025 | $3.33 | $2.47 | +35.0% | +6.7% | +6.7% |
| Q2 FY2025 | $3.16 | $2.31 | +36.6% | +3.9% | +3.5% |
| Q1 FY2024 | $3.22 | $2.42 | +33.0% | +4.6% | +5.3% |
| Q4 FY2024 | $3.30 | $2.47 | +33.8% | -4.3% | -4.1% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Dror BashanCEO3 yr 2 mo21 callsCurrentSample
CEO since 2023 • 9/12 beats (75%) • guidance suspended Q3 FY2026
- Gilad MamlokCFO10 mo3 callsCurrentSample
CFO since 2025 • 1/4 beats (25%) • guidance suspended Q3 FY2026
- Yaron NaosSr. VP, Operations3 yr 9 mono recorded callsCurrentSample
OTHER since 2022 • 7/16 beats (44%) • last guidance raise Q1 FY2026
- Eyal RubinCFO2 yr18 callsFormerSample
CFO since 2022 • 12/16 beats (75%) • last call held guidance Q2 FY2026
- Yael HayonVP, Research & Development11 mono recorded callsFormerSample
OTHER since 2022 • 6/16 beats (38%) • last guidance raise Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PLX.
$ curl https://api.spokenalpha.com/v1/companies/PLXFAQ
Frequently asked about PLX
Where can I find Protalix BioTherapeutics, Inc.'s (PLX) earnings call transcripts?
Spoken Alpha indexes PLX's earnings call transcripts at https://spokenalpha.com/companies/PLX. Each call links to attributed speakers and parsed analyst Q&A. Protalix BioTherapeutics, Inc.'s own investor relations page is at https://ir.protalix.com/.
When was Protalix BioTherapeutics, Inc.'s most recent earnings call?
Protalix BioTherapeutics, Inc. (PLX) held its most recent earnings call on 2026-05-13, covering fiscal Q1 2026.
What sector is PLX in?
Protalix BioTherapeutics, Inc. (PLX) operates in the Healthcare sector (Biotechnology industry).